SCHEMBL6038899

SCHEMBL6038899

CCOc1cccc(COc2nccnc2NS(=O)(=O)c2ccc(C)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.47
AR P10275 1/20 0.47
ALDH1A1 P00352 5/20 0.44
LMNA P02545 4/20 0.44
PKM P14618 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 5/20 0.44
MEN1 O00255 3/20 0.44
PPIF P30405 1/20 0.44
MAPT P10636 2/20 0.44
CCR4 P51679 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ALOX15 P16050 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NR2F2 P24468 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038839 0.91 F2 (0.49) F2ARALDH1A1LMNASMN1; SMN2
SCHEMBL6038504 0.91 MEN1 (0.50) F2ARALDH1A1LMNAPKM
SCHEMBL6038316 0.90 F2 (0.46) F2ARALDH1A1LMNASMN1; SMN2
SCHEMBL6038407 0.89 F2 (0.45) F2ARALDH1A1SMN1; SMN2KMT2A
SCHEMBL6039298 0.89 AR (0.51) F2ARALDH1A1LMNASMN1; SMN2
SCHEMBL6038428 0.88 F2 (0.48) F2ARALDH1A1KMT2AMEN1
SCHEMBL6038725 0.88 KMT2A (0.48) F2ARALDH1A1LMNASMN1; SMN2
SCHEMBL6038680 0.88 F2 (0.46) F2ARALDH1A1KMT2AMEN1
SCHEMBL6038609 0.86 CCR4 (0.50) F2ARALDH1A1PPIFMAPT
SCHEMBL6039011 0.85 KMT2A (0.47) ARALDH1A1HPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 F2 2305/4885AR 422/4885ALDH1A1 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.